Literature DB >> 15653409

T cell response in hepatitis C virus infection.

C Neumann-Haefelin1, H E Blum, F V Chisari, R Thimme.   

Abstract

Hepatitis C virus (HCV) is a hepatotropic RNA virus that causes acute and chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. It is widely accepted that cellular immune responses play an important role in viral clearance and disease pathogenesis. However, HCV often evades effective immune recognition and has a propensity to persist in the majority of acutely infected individuals (ca. 80%). The immunological and virological basis for the inefficiency of the cellular immune response to clear or control the virus is not known. Recent studies, however, have provided new insights into the mechanisms of viral clearance and persistence that will be discussed in detail.

Entities:  

Mesh:

Year:  2005        PMID: 15653409     DOI: 10.1016/j.jcv.2004.05.008

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  22 in total

1.  Human leukocyte antigen class II DQB1*0301, DRB1*1101 alleles and spontaneous clearance of hepatitis C virus infection: a meta-analysis.

Authors:  Xin Hong; Rong-Bin Yu; Nan-Xiong Sun; Bin Wang; Yao-Chu Xu; Guan-Ling Wu
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

2.  Elicitation of strong immune responses by a DNA vaccine expressing a secreted form of hepatitis C virus envelope protein E2 in murine and porcine animal models.

Authors:  Yi-Ping Li; Hye-Na Kang; Lorne-A Babiuk; Qiang Liu
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

3.  Thymic stromal lymphopoietin transgenic mice develop cryoglobulinemia and hepatitis with similarities to human hepatitis C liver disease.

Authors:  Jolanta Kowalewska; Anja S Mühlfeld; Kelly L Hudkins; Matthew M Yeh; Andrew G Farr; Jeffrey V Ravetch; Charles E Alpers
Journal:  Am J Pathol       Date:  2007-03       Impact factor: 4.307

Review 4.  Host and viral factors contributing to CD8+ T cell failure in hepatitis C virus infection.

Authors:  Christoph Neumann-Haefelin; Hans-Christian Spangenberg; Hubert-E Blum; Robert Thimme
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

5.  A novel, helminth-derived immunostimulant enhances human recall responses to hepatitis C virus and tetanus toxoid and is dependent on CD56+ cells for its action.

Authors:  A J MacDonald; N A Libri; S Lustigman; S J Barker; M A Whelan; A E Semper; W M Rosenberg
Journal:  Clin Exp Immunol       Date:  2008-03-12       Impact factor: 4.330

Review 6.  Drugs in development for hepatitis C.

Authors:  Rudolf E Stauber; Harald H Kessler
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  Endogenous cytotoxic T-cell response contributes to the long-term antiretroviral protection induced by a short period of antibody-based immunotherapy of neonatally infected mice.

Authors:  Laurent Gros; Mireia Pelegrin; Henri-Alexandre Michaud; Stéphanie Bianco; Javier Hernandez; Chantal Jacquet; Marc Piechaczyk
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

8.  Control of virus-specific CD8+ T-cell exhaustion and immune-mediated pathology by E3 ubiquitin ligase Cbl-b during chronic viral infection.

Authors:  Rong Ou; Menghua Zhang; Lei Huang; Demetrius Moskophidis
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

9.  Maintenance of Th1 hepatitis C virus (HCV)-specific responses in individuals with acute HCV who achieve sustained virological clearance after treatment.

Authors:  Jacqueline K Flynn; Gregory J Dore; Margaret Hellard; Barbara Yeung; William D Rawlinson; Peter A White; John M Kaldor; Andrew R Lloyd; Rosemary A Ffrench
Journal:  J Gastroenterol Hepatol       Date:  2013-11       Impact factor: 4.029

10.  Phenotypic and functional alterations of primary human PBMCs induced by HCV non-enveloped capsid-like particles uptake.

Authors:  Polyxeni P Doumba; Elisavet Serti; Maria Boutsikou; Manousos M Konstadoulakis; Urania Georgopoulou; John Koskinas
Journal:  Cell Mol Life Sci       Date:  2013-05-05       Impact factor: 9.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.